Tesaro (TSRO) PT Raised to $128 at RBC Capital
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
RBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.
Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative population shows a stat sig benefit, which allows TSRO to file broadly for platinum sensitive ovarian cancer patients, the broadest addressable market and an upside scenario, and safety/tolerability differences could point to further PARP inhibitor separation. Niraparib is the PARP inhibitor to beat and there is no legitimate competitive threat near-term. PT to $128 from $122."
Shares of Tesaro closed at $99.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Cuts Price Target on Pentair (PNR) to $66 Following 3Q Report
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!